Abeona Therapeutics Reports Third Quarter 2022 Financial Results

Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023

Company well-funded with expected cash runway into 3Q 2024

NEW YORK and CLEVELAND, Nov. 14, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced financial results for the third quarter of 2022.

“The positive topline data from the Phase 3 VIITAL study provides strong support for EB-101’s potential and validation of the Abeona team’s extensive efforts,” said Vish Seshadri, Chief Executive Officer of Abeona. “This is an exciting time for Abeona as we are sharply focused on submitting a Biologics License Application for EB-101 to the U.S. FDA. With the additional capital raised after quarter-end, we are now well-funded into the third quarter of 2024, beyond the anticipated timing for potential BLA approval.”

Third Quarter and Recent Operating Highlights

EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)

  • On November 3, 2022, Abeona announced positive topline data from the pivotal Phase 3 VIITAL study of investigational EB-101 in RDEB. The VIITAL study met its two co-primary efficacy endpoints demonstrating statistically significant, clinically meaningful improvements in wound healing and pain reduction in large chronic RDEB wounds. The Company intends to present more detailed results from this study at future medical meetings and in a peer-reviewed journal.
  • Based on the positive VIITAL topline results, the Company plans to submit a Biologics License Application (BLA) for EB-101 to the U.S. Food and Drug Administration (FDA) in the second quarter of 2023. If the BLA is approved, Abeona may be eligible for a Priority Review Voucher (PRV), which can be used to receive expedited review by the FDA of a subsequent marketing application for a different product or sold to another company.
  • Long-term follow up data up to eight years and quality of life data from a completed Phase 1/2a study of EB-101 in RDEB were published in Orphanet Journal of Rare Diseases. The data showed that large chronic RDEB wounds treated with EB-101 had sustained wound healing with mean 5.9 years of follow-up, and long-term symptomatic relief, including reduction in pain and itch.

Preclinical programs

  • Abeona’s preclinical programs are investigating the use of novel adeno-associated virus (AAV) capsids in AAV-based therapies for five undisclosed ophthalmic conditions. The Company has generated appropriate mouse models, produced research grade vectors, and started dosing mice in proof-of-concept studies to support possible pre-Investigational New Drug Application (IND) meetings with the FDA in early 2023.

Corporate highlights

  • On November 3, 2022, the Company announced a private placement financing with gross proceeds of $35.0 million. The private placement included participation from new and existing institutional investors.

Third Quarter Financial Results

Cash, cash equivalents, restricted cash and short-term investments totaled $23.5 million as of September 30, 2022. Net cash used in operating activities was $6.8 million for the third quarter of 2022, compared to $9.0 million in the second quarter of 2022. Abeona estimates that its current cash and cash equivalents, restricted cash and short-term investments plus the net proceeds from the private placement financing on November 3, 2022 are sufficient resources to fund operations into the third quarter of 2024.

Research and development (R&D) expenses for the three months ended September 30, 2022 were $5.5 million, compared to $9.1 million for the same period of 2021. General and administrative (G&A) expenses were $3.9 million for the three months ended September 30, 2022, compared to $5.8 million for the same period of 2021.

Net loss attributable to common shareholders for the third quarter of 2022 was $9.5 million, or $1.48 loss per common share as compared to $7.0 million, or $1.80 loss per common share, in the third quarter of 2021.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s lead clinical program is EB-101, its investigational autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Abeona’s fully integrated cell and gene therapy cGMP manufacturing facility produced EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and potential commercial production of AAV-based gene therapies. For more information, visit www.abeonatherapeutics.com.

Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “plans,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and outcome of our Biologics License Application submission to the FDA for EB-101; our ability to fund operations with current cash and cash equivalents, restricted cash and short-term investments plus the net proceeds from our November 2022 private placement; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of any future meetings with the FDA or other regulatory agencies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)

    For the three months ended September 30,   For the nine months ended September 30,
      2022       2021       2022       2021  
License and other revenues   $     $     $ 1,346     $  
Royalties                 350        
Research and development     5,490       9,056       22,693       25,923  
General and administrative     3,890       5,816       11,574       17,261  
Impairment of licensed technology                 1,355        
Impairment of right-of-use lease asset                 1,561        
Impairment of construction-in-progress                 1,792        
Total expenses     9,380       14,872       39,325       43,184  
Loss from operations     (9,380 )     (14,872 )     (37,979 )     (43,184 )
Gain on settlement with licensor           6,743             6,743  
PPP loan payable forgiveness income           1,758             1,758  
Interest income     72       7       103       35  
Interest expense     (157 )     (683 )     (558 )     (3,603 )
Other income (expense)     (19 )     3       (136 )     (2 )
Net loss   $ (9,484 )   $ (7,044 )   $ (38,570 )   $ (38,253 )
Deemed dividends related to Series A and Series B                
Convertible Redeemable Preferred Stock                 (3,782 )      
Net loss attributable to Common Shareholders   $ (9,484 )   $ (7,044 )   $ (42,352 )   $ (38,253 )
Basic and diluted loss per common share   $ (1.48 )   $ (1.80 )   $ (7.05 )   $ (9.93 )
Weighted average number of common                
shares outstanding – basic and diluted     6,421,245       3,924,024       6,009,902       3,853,318  
Other comprehensive income (loss):                
Change in unrealized gains (losses) related to available-for-sale debt securities     (4 )     1       (11 )     10  
Foreign currency translation adjustments     (6 )     (9 )     (6 )     (9 )
Comprehensive loss   $ (9,494 )   $ (7,052 )   $ (42,369 )   $ (38,252 )

Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)

ASSETS September 30,
  December 31,
Current assets:      
Cash and cash equivalents $ 5,733     $ 32,938  
Short-term investments   12,434       12,086  
Restricted cash   5,338       5,891  
Accounts receivable         3,000  
Other receivables   1,047        
Prepaid expenses and other current assets   945       2,377  
Total current assets   25,497       56,292  
Property and equipment, net   6,606       12,339  
Right-of-use lease assets   6,638       9,403  
Licensed technology, net         1,384  
Other assets   20       168  
Total assets $ 38,761     $ 79,586  
Current liabilities:      
Accounts payable $ 1,748     $ 4,325  
Accrued expenses   4,121       5,585  
Current portion of lease liability   1,810       1,818  
Current portion of payable to licensor   4,921       4,599  
Deferred revenue         296  
Total current liabilities   12,600       16,623  
Payable to licensor   4,064       3,828  
Other long-term liabilities   200       200  
Long-term lease liabilities   6,484       7,560  
Total liabilities   23,348       28,211  
Commitments and contingencies      
Stockholders’ equity:      
Preferred stock – $0.01 par value; authorized 2,000,000 shares;      
No shares issued and outstanding as of September 30, 2022 and      
December 31, 2021, respectively          
Common stock – $0.01 par value; authorized 200,000,000 shares;      
7,671,351 and 5,888,217 shares issued and outstanding as of      
September 30, 2022 and December 31, 2021, respectively*   77       1,472  
Additional paid-in capital   709,590       705,570  
Accumulated deficit   (694,210 )     (655,640 )
Accumulated other comprehensive loss   (44 )     (27 )
Total stockholders’ equity   15,413       51,375  
Total liabilities and stockholders’ equity $ 38,761     $ 79,586  

* As of November 7, 2022, Abeona had 17,175,799 shares of common stock outstanding.


CONTACT: Investor and Media Contact:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics

error: Content is protected !!